Skip to main content
Top
Published in: BMC Cancer 1/2020

01-12-2020 | Nephrostomy | Research article

Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer

Authors: Marie C. Hupe, Lukas Dormayer, Tomasz Ozimek, Julian P. Struck, Martin J. P. Hennig, Melanie Klee, Christoph A. J. von Klot, Markus A. Kuczyk, Axel S. Merseburger, Mario W. Kramer

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Whether or not double J (DJ) stenting during transurethral resection of a bladder tumour (TURBT) harms patients with regard to possible metachronous upper urinary tract urothelial cancer (UUTUC) development remains controversial. This study evaluated the impact of DJ compared to nephrostomy placement during TURBT for bladder cancer (BCa) on the incidence of metachronous UUTUCs.

Methods

We retrospectively analysed 637 patients who underwent TURBT in our department between 2008 and 2016. BCa, UUTUC and urinary drainage data (retrograde/anterograde DJ and percutaneous nephrostomy) were assessed, along with the prevalence of hydronephrosis, and mortality. Chi-square and Fisher’s exact test was performed for univariate analyses. Survival analysis was performed by the Kaplan-Meier method and log-rank tests.

Results

UUTUC was noted in 28 out of 637 patients (4.4%), whereas only eight (1.3%) developed it metachronously to BCa. Out of these, four patients received DJ stents, while four patients received no urinary drainage of the upper urinary tract. Placement of urinary drainage significantly correlated with UUTUC (50.0% vs. 17.9%; p = 0.041). DJ stenting significantly correlated with UUTUC (50.0% vs. 11%; p <  0.01), while no patient with a nephrostomy tube developed UUTUC. UUTUC-free survival rates were significantly lower for patients with DJ stents than for all other patients (p = 0.001). Patients with or without DJ stents had similar overall survival (OS) rates (p = 0.73), whereas patients with nephrostomy tubes had significantly lower OS rates than all other patients (p <  0.001).

Conclusions

Patients with DJ stenting during TURBT for BCa might have an increased risk of developing metachronous UUTUC. This study indicated advantages in placing nephrostomy tubes rather than DJ stents; however, confirmation requires investigation of a larger cohort. Even so, the increased mortality rate in the nephrostomy group reflected hydronephrosis as an unfavourable prognostic factor.
Literature
1.
go back to reference Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111–22.CrossRef Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111–22.CrossRef
2.
go back to reference Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol. 2013;31:141–5.CrossRef Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol. 2013;31:141–5.CrossRef
3.
go back to reference Takaoka E, Hinotsu S, Joraku A, et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol. 2010;17:623–8.CrossRef Takaoka E, Hinotsu S, Joraku A, et al. Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol. 2010;17:623–8.CrossRef
4.
go back to reference Palou J, Rodríguez-Rubio F, Huguet J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005;174:859–61 discussion 861.CrossRef Palou J, Rodríguez-Rubio F, Huguet J, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005;174:859–61 discussion 861.CrossRef
5.
go back to reference Perlis N, Turker P, Bostrom PJ, et al. Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. World J Urol. 2013;31:161–7.CrossRef Perlis N, Turker P, Bostrom PJ, et al. Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. World J Urol. 2013;31:161–7.CrossRef
6.
go back to reference Picozzi S, Ricci C, Gaeta M, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012;188:2046–54.CrossRef Picozzi S, Ricci C, Gaeta M, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012;188:2046–54.CrossRef
7.
go back to reference Tollefson MK, Blute ML, Farmer SA, Frank I. Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol. 2010;183:81–6.CrossRef Tollefson MK, Blute ML, Farmer SA, Frank I. Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol. 2010;183:81–6.CrossRef
8.
go back to reference Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk? J Urol. 2009;182:2632–7.CrossRef Volkmer BG, Schnoeller T, Kuefer R, Gust K, Finter F, Hautmann RE. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk? J Urol. 2009;182:2632–7.CrossRef
9.
go back to reference Kiss B, Furrer MA, Wuethrich PY, Burkhard FC, Thalmann GN, Roth B. Stenting prior to cystectomy is an independent risk factor for upper urinary tract recurrence. J Urol. 2017;198:1263–8.CrossRef Kiss B, Furrer MA, Wuethrich PY, Burkhard FC, Thalmann GN, Roth B. Stenting prior to cystectomy is an independent risk factor for upper urinary tract recurrence. J Urol. 2017;198:1263–8.CrossRef
10.
go back to reference Huguet-Pérez J, Palou J, Millán-Rodríguez F, Salvador-Bayarri J, Villavicencio-Mavrich H, Vicente-Rodríguez J. Upper tract transitional cell carcinoma following cystectomy for bladder cancer. Eur Urol. 2001;40:318–23.CrossRef Huguet-Pérez J, Palou J, Millán-Rodríguez F, Salvador-Bayarri J, Villavicencio-Mavrich H, Vicente-Rodríguez J. Upper tract transitional cell carcinoma following cystectomy for bladder cancer. Eur Urol. 2001;40:318–23.CrossRef
11.
go back to reference Wright JL, Hotaling J, Porter MP. Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis. J Urol. 2009;181:1035–9 discussion 1039.CrossRef Wright JL, Hotaling J, Porter MP. Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis. J Urol. 2009;181:1035–9 discussion 1039.CrossRef
12.
go back to reference Chou EC, Lin AT, Chen KK, Chang LS. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors. Int J Urol. 2006;13:682–5.CrossRef Chou EC, Lin AT, Chen KK, Chang LS. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors. Int J Urol. 2006;13:682–5.CrossRef
13.
go back to reference Divrik RT, Sahin A, Altok M, Unlü N, Zorlu F. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J Urol. 2007;178:802–6 discussion 806.CrossRef Divrik RT, Sahin A, Altok M, Unlü N, Zorlu F. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J Urol. 2007;178:802–6 discussion 806.CrossRef
14.
go back to reference Hofner T, Haferkamp A, Knapp L, et al. Preoperative hydronephrosis predicts advanced bladder cancer but is not an independent factor for cancer-specific survival after radical cystectomy. Urol Int. 2011;86:25–30.CrossRef Hofner T, Haferkamp A, Knapp L, et al. Preoperative hydronephrosis predicts advanced bladder cancer but is not an independent factor for cancer-specific survival after radical cystectomy. Urol Int. 2011;86:25–30.CrossRef
15.
go back to reference Oh JJ, Byun SS, Jeong CW, Kwak C, Kim HH, Ku JH. Association between preoperative hydronephrosis and prognosis after radical cystectomy among patients with bladder cancer: a systemic review and meta-analysis. Front Oncol. 2019;9:158.CrossRef Oh JJ, Byun SS, Jeong CW, Kwak C, Kim HH, Ku JH. Association between preoperative hydronephrosis and prognosis after radical cystectomy among patients with bladder cancer: a systemic review and meta-analysis. Front Oncol. 2019;9:158.CrossRef
16.
go back to reference Mano R, Shoshany O, Baniel J, Yossepowitch O. Resection of ureteral orifice during transurethral resection of bladder tumor: functional and oncologic implications. J Urol. 2012;188:2129–33.CrossRef Mano R, Shoshany O, Baniel J, Yossepowitch O. Resection of ureteral orifice during transurethral resection of bladder tumor: functional and oncologic implications. J Urol. 2012;188:2129–33.CrossRef
17.
go back to reference Altok M, Sahin AF, Gokce MI, Ekin GR, Divrik RT. Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes. Int Braz J Urol. 2017;43:1052–9.CrossRef Altok M, Sahin AF, Gokce MI, Ekin GR, Divrik RT. Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes. Int Braz J Urol. 2017;43:1052–9.CrossRef
Metadata
Title
Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer
Authors
Marie C. Hupe
Lukas Dormayer
Tomasz Ozimek
Julian P. Struck
Martin J. P. Hennig
Melanie Klee
Christoph A. J. von Klot
Markus A. Kuczyk
Axel S. Merseburger
Mario W. Kramer
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-6620-2

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine